Skip to content

Clinical study on the treatment of frail elderly patients with Shengyu decoction

Clinical study on the treatment of frail elderly patients with Shengyu decoction

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000408
Enrollment
Unknown
Registered
2026-02-25
Start date
2023-07-01
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Frailty

Interventions

Control group:Basic treatment, including low-intensity, high-frequency, long-term exercise prescriptions and nutritional support educationBasic treatment, including low-intensity, high-frequency, long
Shengyu decoction group:Basic treatment + Shengyu decoction

Sponsors

Huadong hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 95 Years

Inclusion criteria

Inclusion criteria: 1. Age = 60 years old; 2. Able to understand and sign informed consent forms; 3. Patients who meet the diagnostic criteria for frailty in the elderly (Freid frailty phenotype).

Exclusion criteria

Exclusion criteria: 1. Suffering from serious systemic diseases such as heart, brain, liver, kidney, blood, respiratory, digestive, etc; 2. Have a history of mental illness or serious psychological problems; 3. Individuals with acute and/or chronic infectious diseases; 4. Individuals with allergies or allergies to the ingredients of this medicine, as well as those with weak constitutions; 5. Those who do not meet the inclusion criteria, fail to use medication as prescribed, complete treatment, cannot judge efficacy, or have incomplete data that affect efficacy or safety assessment; 6. Patients with malignant tumors; 7. Patients with severe arrhythmia detected by electrocardiogram examination; 8. Deterioration of heart failure due to stroke, transient ischemic attack, acute coronary syndrome, or hospitalization within the first six months of the observation period; 9. Participate in other clinical trials three months before randomization; 10. Any other conditions or treatments that may make the patient unsuitable for the clinical study.

Design outcomes

Primary

MeasureTime frame
Frailty phenotype scale score;

Secondary

MeasureTime frame
Short Physical Performance Battery;

Countries

China

Contacts

Public ContactTao Wu

Huadong hospital

taowuh@hotmail.com13641673915

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Mar 14, 2026